Last edition
News about
Mabylon Advances Peanut Allergy Drug MY006 After Positive Early Clinical Data
Mabylon AG has reported positive preliminary Phase Ia results for MY006, its antibody-based peanut allergy treatment candidate, while also advancing a second allergy programme targeting tree pollen allergens.
InMed Pharmaceuticals and Mentari Therapeutics Mergers to Advance Next-Generation Migraine Therapies
InMed Pharmaceuticals and Mentari Therapeutics have entered into a definitive merger agreement, combining Mentari’s migraine-focused drug pipeline with InMed’s public market infrastructure to support the development of innovative therapies targeting chronic and episodic migraine.
Pfizer Reports Positive Phase 2 Results for Pediatric Pneumococcal Vaccine Program
Pfizer reports strong phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing enhanced serotype 3 immune response, broad protection across 25 serotypes, and a favorable safety profile ahead of Phase 3 development.
Zydus Lifesciences Completes Investment in Torrent Urja 25 with Rs 90.18 Million Share Subscription
Zydus Lifesciences and its subsidiaries have completed the final tranche of investment in Torrent Urja 25, subscribing to equity shares worth Rs 90.18 million and concluding the transaction initiated under the Share Subscription and Shareholders’ Agreements (SSSAs).
Bayer Wins US FDA Priority Review for Asundexian Stroke Prevention Therapy
Bayer receives US Food and Drug Administration Priority Review (PR) for asundexian to reduce recurrent stroke risk after non-cardioembolic ischemic stroke or transient ischemic attack, supported by positive phase 3 OCEANIC-STROKE trial results.
AstraZeneca Wins US Approval for Baxfendy, First Aldosterone Synthase Inhibitor for Hypertension
AstraZeneca receives US approval for Baxfendy, the first Aldosterone Synthase Inhibitor (ASI) for adults with hypertension, supported by phase 3 BaxHTN trial results showing significant reductions in systolic blood pressure.
Parexel Launches ParexelAI to Speed Up Clinical Development
Parexel launches ParexelAI, a proprietary Artificial Intelligence (AI) platform designed to accelerate clinical development by improving trial speed, efficiency, and data quality for sponsors and patients.
Lupin Gets US FDA Tentative Approval for Revefenacin Inhalation Solution
Lupin receives tentative US Food and Drug Administration (FDA) approval for Revefenacin Inhalation Solution, a generic version of Yupelri for maintenance treatment of Chronic
Obstructive Pulmonary Disease (COPD).<br />
Accord BioPharma has received US FDA approval for Immgolis and Immgolis Intri, the first golimumab biosimilars approved in the United States for rheumatoid arthritis and ulcerative colitis treatment.
Indian Pharmacist Association Distances Itself From Proposed Nationwide Pharmacy Strike
Indian Pharmacist Association has announced that it will not support the nationwide pharmacy strike called by All India Organisation of Chemists and Druggists, joining several state-level trade and pharmacist bodies that have rejected the bandh.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy